Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6765 · 8 trials · 4 indications
A 10-item scale for the evaluation of depressive symptoms. Each MADRS item is rated on a 0 to 6 scale. The MADRS total score is calculated as the sum of the 10 individual item scores; the total score can range from 0 to 60. Higher MADRS scores indicate higher levels of depressive symptoms.
Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item instrument used for the evaluation of depressive symptoms. Each item is rated on a scale of 0 to 6 (with higher scores indicating more severe depression). The individual item scores are added together to form a total score, ranging between 0 and 60. 0 is considered the best score, 60 the worst.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| AZD6765 (150 mg) / Placebo | EXPERIMENTAL | Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period. |
| Placebo / AZD6765 (150 mg) | PLACEBO_COMPARATOR | Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period. |
| 150 mg [14C] AZD6765 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD6765 iv | DRUG | 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion. |
| Placebo | DRUG | 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion |
| AZD6765 | DRUG | Single IV infusion of 150 mg AZD6765. |
| Placebo to AZD6765 | DRUG | Single IV infusion of Placebo to AZD6765 |
| 150 mg [14C] AZD6765 | RADIATION | - |
| midazolam | DRUG | - |
| Ketamine | DRUG | single infusion |
Inclusion Criteria: * Provision of signed and dated informed consent before initiation of any study-related procedures. * Male or female patients aged 18 to 70 years, inclusive. * The patient must have a clinical diagnosis of major depressive disorder with a lifetime history of inadequate response ...
AZD6765 is an investigational small molecule being studied for the treatment of depression, including major depressive disorder and treatment resistant major depressive disorder. It has been evaluated in clinical trials for these psychiatric conditions.
AZD6765 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN.
AZD6765 has completed Phase 2 clinical trials for depression and treatment resistant major depressive disorder. It remains an investigational drug and is not approved by regulatory authorities.
AZD6765 has been studied in several completed trials, including NCT00491686 for treatment resistant depression, NCT00986479 for treatment resistant major depressive disorder, NCT01046630 for depression using pharmaco MRI, and NCT01217645 for drug metabolism and excretion.
AZD6765 is also known by the chemical name [14C]AZD6765 in a study assessing its distribution, metabolism, and excretion after a single-dose intravenous administration.